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Available online 12 July 2016Primary ovarian carcinoid tumors are exceptionally rare entities accounting for approximately 0.1% of all ovarian
neoplasms. This report describes a primary ovarian neuroendocrine tumor arising in association with a mature
cystic teratoma in a 65 year-old woman. Macroscopically, the unilateral adnexal tumor was composed of cystic,
solid and mucinous elements which resolved into a dual component lesion histologically. The majority of the
tumor displayed an organoid architecturewithmild tomoderate pleomorphism and no discerniblemitotic activ-
ity,while approximately 10% consisted of sheets and groups of cells with highly pleomorphic nuclei, necrosis and
occasional mitoses. Features of amature cystic teratomawere seen very focally. Immunohistochemistry revealed
strong, diffuse positivity for CD56 and synaptophysin. Chromogranin immunonegativity was noted and there
was an absence of nuclearβ-catenin accumulation. Ki-67 indexwas 10–12%. Although there is no established di-
agnostic framework for primary ovarian carcinoid tumors, this case was diagnosed as a well-differentiated neu-
roendocrine tumor, Grade 2 (intermediate grade), arising in association with a mature cystic teratoma/dermoid
cyst. This case highlights the need to develop ovarian diagnostic criteria in this area.
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Neuroendocrine tumors are a group of epithelial neoplasms with a
predominantly neuroendocrine differentiation that can affect almost
any organ system (Klimstra et al., 2010). Although these are typically as-
sociated with the gastrointestinal tract, pancreas and lung, gynecologi-
cal cases have also been reported in the cervix, endometrium and
ovaries (Fisseler-Eckhoff and Demes, 2012; Kupryjańczyk, 1997; Chun,
2015). Amongst these, primary ovarian carcinoid tumors are exception-
ally rare, accounting for approximately 0.1% of all ovarian and 0.5% of all
carcinoid neoplasms (Modlin and Sador, 1997; Modlin et al., 2003).
Only 15% of these reportedly exist in pure form,with the remainder fea-
turing teratomatous components such as struma ovarii or dermoid cysts
(Fisseler-Eckhoff and Demes, 2012; Kupryjańczyk, 1997; Talerman,
1984). This report describes an unusual case of primary ovarian neuro-
endocrine tumor arising in association with a mature cystic teratoma,
and highlights the diagnostic challenges posed by these neoplasms in
the absence of a consensus ovarian classification system.gy, Level 5, St James's University
r Inc. This is an open access article un2. Case presentation
A 65-year-old Caucasian woman with a BMI of 28.8 kg/m2 was re-
ferred as a fast-track patient for an abdominal mass and raised CA 125
following a three-week period of refractory diarrhea. Transvaginal ul-
trasound revealed a large, complex and predominantly vascular cystic
mass extending from the pelvis to the umbilicus which was
14 × 14 × 9 cm in size. The uterus was retroverted with an endometrial
thickness of 15 mm and no evidence of vascular enhancement. The
kidneys were normal and there was a small amount of subphrenic
ascites. A moderate right pleural effusion was noted. Subsequent CT
abdomen and pelvis with contrast confirmed a large pelvic mass with
a small volume of ascites but no convincing metastases. Her past medi-
cal history included carcinoid heart diseasewithmoderate to severe left
ventricular dysfunction and severe tricuspid regurgitation. Preoperative
hematological profile was within normal limits; CA 125 was 248 units/
ml and CEA3.0 ng/ml. Urinary 5-hydroxyindoleacetic acid (5-HIAA) and
chromogranin Awere both raised at 771mg/24h and 338.6 μg/l, respec-
tively. The patient underwent a total abdominal hysterectomy, bilateral
salpingo-oophorectomy, pelvic and para-aortic lymphadenectomy and
omentectomy for presumed carcinoid syndrome. Postoperative recov-
ery was uneventful and she was discharged after 7 days with routine
follow-up.der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Macroscopically, the right adnexa was enlarged, nodular and cystic,
andmeasured 130 × 130 × 85mm. It weighed 654 g and had a smooth,
intact capsular surface incorporating the fimbrial end of the fallopian
tube. Slicing of the specimen revealed cystic areas filled with hemor-
rhagic fluid, a tan colored solid component and mucinous elements.
The allied uterus, cervix, left tube and ovary, and all lymph nodes
were broadly unremarkable and of dimensions and appearances within
normal limits, other than for the incidental finding of a fibroid in the an-
terior uterine wall.
Histologically, the ovarian tumor exhibited two components. Ap-
proximately 90% of themain tumor was composed of an insular pattern
resembling a carcinoid tumor with nested areas, together with foci of
tumor cells arranged in groups and trabeculae (Fig. 1) within an unre-
markable fibrovascular stroma. The nuclei in these areas exhibited
mild to moderate pleomorphism and nomitotic figures were identified.
The remaining 10% of the tumor consisted of sheets and groups of cells
with highly pleomorphic and bizarre nuclei within a vascular stroma.
This component also contained foci of coagulative tumor cell necrosis
and contained 2–3 mitoses per 10 high power fields. Other focal ele-
ments of the tumor were reminiscent of a mature cystic teratoma
(dermoid cyst), featuring cyst-like spaces, variably lined byflat or cuboi-
dal cells, and areas showing duct-like structures resembling skin ap-
pendages. Some of these cystic spaces were also lined by histiocytes
and foreign body-type giant cells. Occasional foci exhibiting neural dif-
ferentiation were also noted.
Immunohistochemistry was performed for chromogranin,
synaptophysin and CD56 given that these have previously been
shown to be expressed in ovarian neuroendocrine tumors (Chun,
2015). Further staining was conducted for β-catenin and Ki-67 (Kim
et al., 2015; Rindi et al., 2006; Rindi et al., 2007; Bosman et al., 2010).
Staining revealed strong, diffuse positivity for CD56 and synaptophysin
(Fig. 2). By contrast, chromogranin was negative in the tumor cells. No
nuclear accumulation of β-catenin was noted. The Ki-67 index was
10–12% in the areas characterized by highly pleomorphic nuclei.Fig. 1. Histology displaying (A) pleomorphic area with bizarre nuclei, (B) areas of nec4. Discussion
The organoid arrangements of tumor cells identifiedwere consistent
with the neuroendocrine differentiation growth patterns described for
these lesions (Klimstra et al., 2010), and the staining patternswere sim-
ilarly supportive. According to theWHO classification of pulmonary and
thymic lesions (Klimstra et al., 2010; Travis, 2004), low to intermediate
grade lesions can be classified into typical and atypical subtypes (with
high grade lesions being either small or large cell carcinomas). The for-
mer should have fewer than 2 mitoses per 10 high power fields (HPFs)
and no necrosis. Their atypical counterparts instead feature 2–10 mito-
ses/10 HPFs or the presence of necrosis. However, as underscored by a
previous case report (Kim et al., 2015), there is a dilemma when
attempting to apply this distinction to ovarian carcinoid tumors. Given
their rarity, there are currently no widely accepted diagnostic criteria
to cover their subclassification or sufficient patient outcome data to re-
late to atypical or aggressive histological appearance. Nevertheless,
based on the presence of N2 mitotic figures/10 HPFs and the presence
of necrotic foci, this tumor fell into the category of atypical (intermedi-
ate grade) carcinoid by applying the criteria set for pulmonary/thymic
lesions. Importantly, necrosis per se is not diagnostic of neuroendocrine
carcinoma; rather, a Ki-67 index of N20% is diagnostic (Rindi et al., 2006;
Rindi et al., 2007; Bosman et al., 2010), which is in excess of what was
recorded for this lesion. In the gastrointestinal tract, a neuroendocrine
tumor with features such as those described for this lesion would be
considered to be a well-differentiated neuroendocrine tumor, Grade 2
(intermediate grade). On balance, we elected to favor this classification
system, resulting in a final diagnosis of well-differentiated neuroendo-
crine tumor, Grade 2 (intermediate grade), arising in association with
a mature cystic teratoma/dermoid cyst.
A previous case report of a similar lesion noted strong nuclear im-
munoreactivity for β-catenin (Kim et al., 2015), an aberrant staining
pattern of aggressive histology associated with both pulmonary neuro-
endocrine carcinomas and atypical carcinoid tumors (Pelosi et al.,
2005). Moreover, this is also described to be an independent predictor
of lymph node spread in patients with atypical pulmonary carcinoidrosis (C) carcinoid-type areas, and (D) adjacent carcinoid and pleomorphic areas.
Fig. 2. Immunohistochemistry displaying (A) Ki67 positivity, (B) diffuse strong positivity for synaptophysin, (C) chromogranin negativity and (D) strong CD56 positivity.
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tion and all four identified lymph nodes were negative for tumor. Al-
though primary ovarian carcinoid tumors' surgical management
reportedly has a good outcome for organ-confined disease (Davis et
al., 1996), these remain poorly studied entities (Gardner et al., 2011)
and as such, attentive followupwas recommended and the casewas re-
ferred to the neuroendocrine multidisciplinary team. Importantly,
clinicoradiological correlation was recommended to exclude the possi-
bility of any other primary site given the obvious impact of metastatic
disease on prognosis (Chun, 2015). The patient continues to be moni-
tored biochemically.
In summary, this case highlights the diagnostic challenges posed by
ovarian carcinoid tumors due to the lack of established diagnostic
criteria available for these rare entities and the need to develop a unified
system towhich ovarianneuroendocrine tumors can be aligned. Further
cases and the accumulation of additional clinical outcome data would
further contribute to improving the accuracy of future prognostic
prediction.
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